From an endocrine perspective, monitoring and shared decision-making usually allow people to maintain the metabolic benefits of therapy while managing menstrual health, unless bleeding or absence severely reduces quality of life
Patients should not discontinue or alter thyroid hormone replacement when using tirzepatide, and close endocrinologic supervision remains essential
However, if you're already taking insulin or sulfonylurea medications (like glyburide), your blood sugar can drop too low because your body now has both the medication and semaglutide working to lower it
This makes maintaining muscle and a low body fat percentage vastly easier after stopping peptides
The need for additional treatment options is thus substantial and is the goal of preclinical studies unraveling neurobiological mechanisms underlying AUD
Hossain A, Yamaguchi F, Matsuo T, et al